Outcomes 18 months after the first human partial face transplantation

被引:286
作者
Dubernard, Jean-Michel
Lengele, Benoit
Morelon, Emmanuel
Testelin, Sylvie
Badet, Lionel
Moure, Christophe
Beziat, Jean-Luc
Dakpe, Stephanie
Kanitakis, Jean
D'Hauthuille, Cedric
El Jaafari, Assia
Petruzzo, Palmina
Lefrancois, Nicole
Taha, Farid
Sirigu, Angela
Di Marco, Giovanni
Carmi, Esther
Bachmann, Danielle
Cremades, Sophie
Giraux, Pascal
Burloux, Gabriel
Hequet, Olivier
Parquet, Nathalie
Frances, Camille
Michallet, Mauricette
Martin, Xavier
Devauchelle, Bernard
机构
[1] Univ Lyon 1, Hop Edouard Herriot, Dept Transplantol, Centaure Network, F-69437 Lyon, France
[2] Catholic Univ Louvain, Brussels, Belgium
[3] Univ Hosp, Amiens, France
[4] Hop St Louis, Paris, France
[5] Hop Tenon, F-75970 Paris, France
关键词
D O I
10.1056/NEJMoa072828
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We performed the first human partial face allograft on November 27, 2005. Here we report outcomes up to 18 months after transplantation. Methods: The postsurgical induction immunosuppression protocol included thymoglobulins combined with tacrolimus, mycophenolate mofetil, and prednisone. Donor hematopoietic stem cells were infused on postoperative days 4 and 11. Sequential biopsy specimens were taken from a sentinel skin graft, the facial skin, and the oral mucosa. Functional progress was assessed by tests of sensory and motor function performed monthly. Psychological support was provided before and after transplantation. Results: Sensitivity to light touch, as assessed with the use of static monofilaments, and sensitivity to heat and cold had returned to normal at 6 months after transplantation. Motor recovery was slower, and labial contact allowing complete mouth closure was achieved at 10 months. Psychological acceptance of the graft progressed as function improved. Rejection episodes occurred on days 18 and 214 after transplantation and were reversed. A decrease in inulin clearance led to a change in immunosuppressive regimen from tacrolimus to sirolimus at 14 months. Extracorporeal photochemotherapy was introduced at 10 months to prevent recurrence of rejection. There have been no subsequent rejection episodes. At 18 months, the patient is satisfied with the aesthetic result. Conclusions: In this patient who underwent the first partial face transplantation, the functional and aesthetic results 18 months after transplantation are satisfactory.
引用
收藏
页码:2451 / 2460
页数:10
相关论文
共 26 条
  • [1] Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction
    Alizadeh, M
    Bernard, M
    Danic, B
    Dauriac, C
    Birebent, B
    Lapart, C
    Lamy, T
    Le Prisé, PY
    Beauplet, A
    Bories, D
    Semana, G
    Quelvennec, E
    [J]. BLOOD, 2002, 99 (12) : 4618 - 4625
  • [2] EXTRACORPOREAL PHOTOCHEMOTHERAPY - EVALUATION OF 2 TECHNIQUES AND USE IN CONNECTIVE-TISSUE DISORDERS
    ANDREU, G
    LEON, A
    HESHMATI, F
    TOD, M
    MENKES, CJ
    BAUDELOT, J
    LAROCHE, L
    [J]. TRANSFUSION SCIENCE, 1994, 15 (04): : 443 - 454
  • [3] LONG-TERM RESULTS OF A CONTROLLED PROSPECTIVE-STUDY WITH TRANSFUSION OF DONOR-SPECIFIC BONE-MARROW IN 57 CADAVERIC RENAL-ALLOGRAFT RECIPIENTS
    BARBER, WH
    MANKIN, JA
    LASKOW, DA
    DEIERHOI, MH
    JULIAN, BA
    CURTIS, JJ
    DIETHELM, AG
    [J]. TRANSPLANTATION, 1991, 51 (01) : 70 - 75
  • [4] Photopheresis for the prevention of rejection in cardiac transplantation
    Barr, ML
    Meiser, BM
    Eisen, HJ
    Roberts, RF
    Livi, U
    Dall'Amico, R
    Dorent, R
    Rogers, JG
    Radovancevic, B
    Taylor, DO
    Jeevanandam, V
    Marboe, CC
    Franco, EL
    Ventura, HO
    Michler, RE
    Griffith, BP
    Boyce, SW
    Reichart, B
    Gandjbakhch, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (24) : 1744 - 1751
  • [5] MICROCHIMERISM FREQUENCY 2 TO 30 YEARS AFTER CADAVERIC KIDNEY-TRANSPLANTATION
    CAILLATZUCMAN, S
    LEGENDRE, C
    SUBERBIELLE, C
    BODEMER, C
    NOEL, LH
    KREIS, H
    BACH, JF
    [J]. HUMAN IMMUNOLOGY, 1994, 41 (01) : 91 - 95
  • [6] Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients
    Ciancio, G
    Burke, GW
    Garcia-Morales, R
    Suzart, K
    Rosen, A
    Ricordi, C
    Kenyon, NS
    Mathew, JM
    Tzakis, AG
    Esquenazi, V
    Miller, J
    [J]. TRANSPLANTATION, 2002, 74 (04) : 488 - 496
  • [7] Six-year clinical effect of donor bone marrow infusions in renal transplant patients
    Ciancio, G
    Miller, J
    Garcia-Morales, RO
    Carreno, M
    Burke, GW
    Roth, D
    Kupin, W
    Tzakis, AG
    Ricordi, C
    Rosen, A
    Fuller, L
    Esquenazi, V
    [J]. TRANSPLANTATION, 2001, 71 (07) : 827 - 835
  • [8] Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients
    Corry, RJ
    Chakrabarti, PK
    Shapiro, R
    Rao, AS
    Dvorchik, I
    Jordan, ML
    Scantlebury, VP
    Vivas, CA
    Fung, JJ
    Starzl, TE
    [J]. ANNALS OF SURGERY, 1999, 230 (03) : 372 - 379
  • [9] Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Couriel, DR
    Hosing, C
    Saliba, R
    Shpall, EJ
    Anderlini, P
    Rhodes, B
    Smith, V
    Khouri, I
    Giralt, S
    de Lima, M
    Hsu, Y
    Ghosh, S
    Neumann, J
    Andersson, B
    Qazilbash, M
    Hymes, S
    Kim, S
    Champlin, R
    Donato, M
    [J]. BLOOD, 2006, 107 (08) : 3074 - 3080
  • [10] Bone marrow-induced tolerance in the era of pancreas and islets transplantation
    Delis, S
    Burke, GW
    Ciancio, G
    [J]. PANCREAS, 2006, 32 (01) : 1 - 8